Lyell Immunopharma (LYEL) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prothena (PRTA) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 21.6% versus a loss of 27.9%. Over five years, PRTA leads with a -83.3% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $422.1 million), about 1.0 times the size.
Prothena converts more of its revenue into profit, with a net margin of -2520.6% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYEL | PRTA |
|---|---|---|
| Share price | $13.80 | $8.22 |
| Market cap | $441.82M | $422.10M |
| 1-day change | +1.62% | -2.14% |
| YTD return | -55.17% | -13.93% |
| 1-year return | -27.86% | -21.56% |
| 5-year return | -92.59% | -83.28% |
| EPS (TTM) | $-12.61 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.00K | $9.68M |
| Revenue growth (YoY) | -40.98% | -92.83% |
| Net income (latest FY) | $-274.45M | $-244.09M |
| Operating margin | -748344.44% | -2216.44% |
| Net margin | -762355.56% | -2520.57% |
| 52-week high | $45.00 | $11.80 |
| 52-week low | $7.20 | $7.70 |
| Distance from 52-week high | -69.33% | -30.34% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +172.68% | +160.34% |
| Average volume | 174.76K | 487.91K |
| Shares outstanding | 32.02M | 51.35M |
| Employees | 161 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Prothena is more profitable, keeping -2520.6 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- Lyell Immunopharma grew revenue faster in its latest fiscal year (-40.98% vs -92.83%).
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
LYEL vs PRTA FAQ
Which is bigger, Lyell Immunopharma or Prothena?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $422.10M for Prothena (PRTA).
Which stock has performed better over the past year, LYEL or PRTA?
PRTA returned -21.56% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Lyell Immunopharma and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.